Molecular insights into microbial β-glucuronidase inhibition to abrogate CPT-11 toxicity

Molecular Pharmacology

Volumn 84, Issue 2, 2013, Pages 208-217

  Roberts, Adam B ^a   Wallace, Bret D ^a   Venkatesh, Madhu Kumar ^b   Mani, Sridhar ^b   Redinbo, Matthew R ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL ENZYME; BETA GLUCURONIDASE; IRINOTECAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG PROTEIN BINDING; ENZYME INHIBITION; ESCHERICHIA COLI; GASTROINTESTINAL TOXICITY; HUMAN; HUMAN CELL; IN VITRO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; CAMPTOTHECIN; CATTLE; DRUG INTERACTIONS; ENZYME INHIBITORS; ESCHERICHIA COLI; FEMALE; GLUCURONIDASE; GLYCOPROTEINS; LIVER; MICE; MICE, INBRED BALB C;

EID: 84880618542     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.113.085852     Document Type: Article

References (51)

1. Abigerges D, Armand JP, Chabot GG, Da Costa L, Fadel E, Cote C, Hérait P, and Gandia D (1994) Irinotecan (CPT-11) high-dose escalation using intensive high-dose loperamide to control diarrhea. J Natl Cancer Inst 86:446-449.
2. Adams PD, Grosse-Kunstleve RW, Hung LW, Ioerger TR, McCoy AJ, Moriarty NW, Read RJ, Sacchettini JC, Sauter NK, and Terwilliger TC (2002) PHENIX: building new software for automated crystallographic structure determination. Acta Crystallogr D Biol Crystallogr 58:1948-1954.
3. Ahmad S, Hughes MA, Lane KT, Redinbo MR, Yeh L-A, and Scott JE (2011) A high throughput assay for discovery of bacterial b-glucuronidase inhibitors. Curr Chem Genomics 5:13-20.
4. Araki E, Ishikawa M, Iigo M, Koide T, Itabashi M, and Hoshi A (1993) Relationship between development of diarrhea and the concentration of SN-38, an active metabolite of CPT-11, in the intestine and the blood plasma of athymic mice following intraperitoneal administration of CPT-11. Jpn J Cancer Res 84:697-702.
5. Brandi G, Dabard J, Raibaud P, Di Battista M, Bridonneau C, Pisi AM, Morselli Labate AM, Pantaleo MA, De Vivo A, and Biasco G (2006) Intestinal microflora and digestive toxicity of irinotecan in mice. Clin Cancer Res 12:1299-1307.
6. Brünger AT (1997) Free R value: cross-validation in crystallography. Methods Enzymol 277:366-396.
7. Cooper HS, Murthy SN, Shah RS, and Sedergran DJ (1993) Clinicopathologic study of dextran sulfate sodium experimental murine colitis. Lab Invest 69:238-249.
8. Cunningham D, Pyrhönen S, James RD, Punt CJ, Hickish TF, Heikkila R, Johannesen TB, Starkhammar H, Topham CA, and Awad L et al. (1998) Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 352:1413-1418.
9. Ducreux M, Köhne C-H, Schwartz GK, and Vanhoefer U (2003) Irinotecan in metastatic colorectal cancer: dose intensification and combination with new agents, including biological response modifiers. Ann Oncol 14 (Suppl 2):ii17-ii23.
10. Emsley P and Cowtan K (2004) Coot: model-building tools for molecular graphics. Acta Crystallogr D Biol Crystallogr 60:2126-2132.
11. Fuchs CS, Moore MR, Harker G, Villa L, Rinaldi D, and Hecht JR (2003) Phase III comparison of two irinotecan dosing regimens in second-line therapy of metastatic colorectal cancer. J Clin Oncol 21:807-814.
12. Graef V, Furuya E, and Nishikaze O (1977) Hydrolysis of steroid glucuronides with beta-glucuronidase preparations from bovine liver, Helix pomatia, and E. coli. Clin Chem 23:532-535.
13. Han J-Y, Shin ES, Lee Y-S, Ghang HY, Kim S-Y, Hwang J-A, Kim JY, and Lee JS (2012) A genome-wide association study for irinotecan-related severe toxicities in patients with advanced non-small-cell lung cancer. Pharmacogenomics J DOI: 10.1038/tpj.2012.24.
14. Hu Z-P, Yang X-X, Chan SY, Xu A-L, Duan W, Zhu Y-Z, Sheu F-S, Boelsterli UA, Chan E, and Zhang Q et al. (2006) St. John's wort attenuates irinotecan-induced diarrhea via down-regulation of intestinal pro-inflammatory cytokines and inhibition of intestinal epithelial apoptosis. Toxicol Appl Pharmacol 216:225-237.
15. Huang P-T, Chen K-C, Prijovich ZM, Cheng T-L, Leu Y-L, and Roffler SR (2011) Enhancement of CPT-11 antitumor activity by adenovirus-mediated expression of b-glucuronidase in tumors. Cancer Gene Ther 18:381-389.
16. Human Microbiome Project Consortium (2012) Structure, function and diversity of the healthy human microbiome. Nature 486:207-214.
17. Jain S, Drendel WB, Chen ZW, Mathews FS, Sly WS, and Grubb JH (1996) Structure of human beta-glucuronidase reveals candidate lysosomal targeting and active-site motifs. Nat Struct Biol 3:375-381.
18. Jo J-C, Lee J-L, Ryu M-H, Chang HM, Kim M, Lee HJ, Kim H-S, Shin J-G, Kim T-W, and Kang Y-K (2012) Phase II and UGT1A1 genotype study of irinotecan dose escalation as salvage therapy for advanced gastric cancer. Br J Cancer 106: 1591-1597.
19. Kambe M, Kikuchi H, Gamo M, Yoshioka T, Ohashi Y, and Kanamaru R (2012) Phase I study of irinotecan by 24-h intravenous infusion in combination with 5-fluorouracil in metastatic colorectal cancer. Int J Clin Oncol 17:150-154.
20. Kawato Y, Aonuma M, Hirota Y, Kuga H, and Sato K (1991) Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11. Cancer Res 51:4187-4191.
21. Kim A, Ueda Y, Naka T, and Enomoto T (2012) Therapeutic strategies in epithelial ovarian cancer. J Exp Clin Cancer Res 31:14.
22. Kurita A, Kado S, Matsumoto T, Asakawa N, Kaneda N, Kato I, Uchida K, Onoue M, and Yokokura T (2011) Streptomycin alleviates irinotecan-induced delayed-onset diarrhea in rats by a mechanism other than inhibition of b-glucuronidase activity in intestinal lumen. Cancer Chemother Pharmacol 67:201-213.
23. Lee KS, Park IH, Nam B-H, and Ro J (2013) Phase II study of irinotecan plus capecitabine in anthracycline-and taxane-pretreated patients with metastatic breast cancer. Invest New Drugs 31:152-159.
24. LoGuidice A, Wallace BD, Bendel L, Redinbo MR, and Boelsterli UA (2012) Pharmacologic targeting of bacterial b-glucuronidase alleviates nonsteroidal antiinflammatory drug-induced enteropathy in mice. J Pharmacol Exp Ther 341: 447-454.
25. Ma MK and McLeod HL (2003) Lessons learned from the irinotecan metabolic pathway. Curr Med Chem 10:41-49.
26. Mathijssen RH, van Alphen RJ, Verweij J, Loos WJ, Nooter K, Stoter G, and Sparreboom A (2001) Clinical pharmacokinetics and metabolism of irinotecan (CPT-11). Clin Cancer Res 7:2182-2194.
27. Matsumura M, Takeshima N, Ota T, Omatsu K, Sakamoto K, Kawamata Y, Umayahara K, Tanaka H, Akiyama F, and Takizawa K (2010) Neoadjuvant chemotherapy followed by radical hysterectomy plus postoperative chemotherapy but no radiotherapy for Stage IB2-IIB cervical cancer-irinotecan and platinum chemotherapy. Gynecol Oncol 119:212-216.
28. Maurice CF, Haiser HJ, and Turnbaugh PJ (2013) Xenobiotics shape the physiology and gene expression of the active human gut microbiome. Cell 152:39-50.
29. McCoy AJ, Grosse-Kunstleve RW, Adams PD, Winn MD, Storoni LC, and Read RJ (2007) Phaser crystallographic software. J Appl Cryst 40:658-674.
30. Nagar S and Blanchard RL (2006) Pharmacogenetics of uridine diphosphoglucuronosyl-transferase (UGT) 1A family members and its role in patient response to irinotecan. Drug Metab Rev 38:393-409.
31. Otwinowski Z and Minor W (1997) Processing of X-ray diffraction data collected in oscillation mode, in Methods in Enzymology (Carter CW Jr and Sweet RM eds) vol 276, pp 307-326, Academic Press, New York.
32. Ray J, Scarpino V, Laing C, and Haskins ME (1999) Biochemical basis of the betaglucuronidase gene defect causing canine mucopolysaccharidosis VII. J Hered 90: 119-123.
33. Reagan-Shaw S, Nihal M, and Ahmad N (2008) Dose translation from animal to human studies revisited. FASEB J 22:659-661.
34. Rothenberg ML, Eckardt JR, Kuhn JG, Burris HA, 3rd, Nelson J, Hilsenbeck SG, Rodriguez GI, Thurman AM, Smith LS, and Eckhardt SG et al. (1996) Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer. J Clin Oncol 14:1128-1135.
35. Rougier P, Bugat R, Douillard JY, Culine S, Suc E, Brunet P, Becouarn Y, Ychou M, Marty M, and Extra JM et al. (1997) Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy. J Clin Oncol 15:251-260.
36. Rougier P, Van Cutsem E, Bajetta E, Niederle N, Possinger K, Labianca R, Navarro M, Morant R, Bleiberg H, and Wils J et al. (1998) Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 352:1407-1412.
37. Saliba F, Hagipantelli R, Misset JL, Bastian G, Vassal G, Bonnay M, Herait P, Cote C, Mahjoubi M, and Mignard D et al. (1998) Pathophysiology and therapy of irinotecan-induced delayed-onset diarrhea in patients with advanced colorectal cancer: a prospective assessment. J Clin Oncol 16:2745-2751.
38. Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, Maroun JA, Ackland SP, Locker PK, and Pirotta N et al.; Irinotecan Study Group (2000) Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 343:905-914.
39. Schüttelkopf AW and van Aalten DMF (2004) PRODRG: a tool for high-throughput crystallography of protein-ligand complexes. Acta Crystallogr D Biol Crystallogr 60:1355-1363.
40. Smith NF, Figg WD, and Sparreboom A (2006) Pharmacogenetics of irinotecan metabolism and transport: an update. Toxicol In Vitro 20:163-175.
41. Sousa T, Paterson R, Moore V, Carlsson A, Abrahamsson B, and Basit AW (2008) The gastrointestinal microbiota as a site for the biotransformation of drugs. Int J Pharm 363:1-25.
42. Spigel DR, Greco FA, Rubin MS, Shipley D, Thompson DS, Lubiner ET, Eakle JF, Quinn R, Burris HA, and Hainsworth JD (2012) Phase II study of maintenance sunitinib following irinotecan and carboplatin as first-line treatment for patients with extensive-stage small-cell lung cancer. Lung Cancer 77:359-364.
43. Stein A, Voigt W, and Jordan K (2010) Chemotherapy-induced diarrhea: pathophysiology, frequency and guideline-based management. Ther Adv Med Oncol 2: 51-63.
44. Takasuna K, Hagiwara T, Hirohashi M, Kato M, Nomura M, Nagai E, Yokoi T, and Kamataki T (1996) Involvement of beta-glucuronidase in intestinal microflora in the intestinal toxicity of the antitumor camptothecin derivative irinotecan hydrochloride (CPT-11) in rats. Cancer Res 56:3752-3757.
45. Takasuna K, Hagiwara T, Hirohashi M, Kato M, Nomura M, Nagai E, Yokoi T, and Kamataki T (1998) Inhibition of intestinal microflora beta-glucuronidase modifies the distribution of the active metabolite of the antitumor agent, irinotecan hydrochloride (CPT-11) in rats. Cancer Chemother Pharmacol 42:280-286.
46. Tobin P, Clarke S, Seale JP, Lee S, Solomon M, Aulds S, Crawford M, Gallagher J, Eyers T, and Rivory L (2006) The in vitro metabolism of irinotecan (CPT-11) by carboxylesterase and beta-glucuronidase in human colorectal tumours. Br J Clin Pharmacol 62:122-129.
47. Tobin PJ, Dodds HM, Clarke S, Schnitzler M, and Rivory LP (2003) The relative contributions of carboxylesterase and beta-glucuronidase in the formation of SN-38 in human colorectal tumours. Oncol Rep 10:1977-1979.
48. Vítek L, Zelenka J, Zadinová M, and Malina J (2005) The impact of intestinal microflora on serum bilirubin levels. J Hepatol 42:238-243.
49. Wallace BD, Wang H, Lane KT, Scott JE, Orans J, Koo JS, Venkatesh M, Jobin C, Yeh L-A, and Mani S et al. (2010) Alleviating cancer drug toxicity by inhibiting a bacterial enzyme. Science 330:831-835.
50. Zaniboni A, Aitini E, Barni S, Ferrari D, Cascinu S, Catalano V, Valmadre G, Ferrara D, Veltri E, and Codignola C et al. (2012) FOLFIRI as second-line chemotherapy for advanced pancreatic cancer: a GISCAD multicenter phase II study. Cancer Chemother Pharmacol 69:1641-1645.
51. Zhao J, Huang L, Belmar N, Buelow R, and Fong T (2004) Oral RDP58 allows CPT-11 dose intensification for enhanced tumor response by decreasing gastrointestinal toxicity. Clin Cancer Res 10:2851-2859.